MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. MOH
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Molina Healthcare (MOH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Molina Healthcare
NYSE•Healthcare•Healthcare Plans
$205.09+2.87(0.01%)After hours
Market Cap
$10.68B
P/S
0.2x
P/B
2.6x

Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces in the United States. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company was founded in 1980 and is headquartered in Long Beach, California.

C

How this company scores

AverageMetricSide Score: 40/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (3/25).

Profitability11/25
Growth11/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality3/25
Strengths
Long cash runwayConsistent growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 35.6x5y range 11.5x – 35.6x
P/E 35.6x · above its 19-quarter median

Currently above its 19-quarter median.

P/S · 0.2x5y range 0.1x – 0.7x
P/S 0.2x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 2.6x5y range 1.6x – 7.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 87.8% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Red Flag

Free cash flow has been negative in 5 of the last 8 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $10.68B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$44.52B
2Q
Q. Revenue
$10.87B
5%
TTM EBITDA
$371.00M
5Q
TTM Op. Income
$203.00M
5Q
Q. Op. Income
$145.00M
2Q
TTM Net Income
$-7.00M
6Q
Q. Net Income
$60.00M
2Q
EPS
$1.19
2Q
Shares Out.
$51.10M
2Q
$44.52B in TTM revenue grew 2.6% YoY, reaching $10.87B last quarter. TTM EBITDA of $371.00M and TTM operating income of $203.00M show growth is flowing through to the bottom line. However, net income is negative at $7.00M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
13.2%
6%
EBITDA Margin
1.7%
2Q
Op. Margin
1.3%
2Q
Net Margin
0.6%
2Q
Op. margin of 1.3% is down 1.9% YoY — costs are rising relative to revenue. Net margin at 0.6% and gross margin of 13.2% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
2Q
P/S Ratio
0.2x
35%
P/B Ratio
2.6x
26%
P/S of 0.2x and P/B of 2.6x. P/S is low relative to typical market levels. Across the last 7 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$16.00B
1%
Cash
$4.99B
11%
Long-Term Debt
$3.77B
4Q
Book Value
$4.17B
2Q
D/E Ratio
0.9
2Q
Debt/EBITDA
20.4
174%
With $16.00B in assets and $3.77B in long-term debt, D/E is 0.9and book value is $4.17B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$-294.00M
3%
TTM Free Cash Flow
$271.00M
2Q
FCF Margin
0.6%
2Q
FCF / Net Income
-38.7
10345%
TTM FCF of $271.00M on $-294.00M in operating cash flow. The FCF / Net Income ratio of -38.7x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 2.6x
· below its 20-quarter median

Currently below its 20-quarter median.

Leverage Risk

Watch

Debt-to-equity has risen 23.2% recently — increasing financial risk even if the current ratio is manageable.

Cash Burn

Watch

5 of the last 8 quarters had negative FCF — inconsistent cash generation raises sustainability concerns.